• Ascletis won FDA clearance to start global Phase III trials of oral GLP-1 candidate ASC30 for long-term weight management.
• Program includes two pivotal 72-week, placebo-controlled studies in the US, Europe, Canada; about 4,600 overweight or obese participants.
• Top-line Phase III data targeted for Q3 2028; US NDA filing planned by end-2028; EU MAA filing targeted for early 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260803-12269208), on August 03, 2026, and is solely responsible for the information contained therein.